- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02466113
A 6 microRNA Tool for Stratifying Stage II Colon Cancer of Receiving Adjuvant Chemotherapy
8. juni 2015 oppdatert av: Wu Song, First Affiliated Hospital, Sun Yat-Sen University
A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Chemotherapy of Stage II Colon Cancer Based on a 6 microRNA Stratified Tool
Whether patients with stage II colon cancer should receive adjuvant chemotherapy or not is still on debate.MicroRNA(miRNA) is a promising tool.
Investigators invented a tool consisting of 6 miRNA(miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215) that was effective to identify one should accept adjuvant chemotherapy or not.
Here investigators randomly assign patients to be assessed by classical pathological features or the miRNA tool of determining who should accept chemotherapy.
Disease free survival and overall survival are the end points of observation.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Detaljert beskrivelse
Investigators randomly assign patients to be assessed by classical pathological features(control group) or the miRNA tool(experimental group).
Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and <12 lymph nodes examined.MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215.
Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)-(0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1).
Investigators defined high risk patient if had any pathological features in control group or the score larger than 1 in the experimental group ,the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
Primary endpoint is the disease free survival and overall survival.
Studietype
Intervensjonell
Registrering (Forventet)
430
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Zehong Chen, master
- Telefonnummer: +8613751773229
- E-post: Stevenchen8@qq.com
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- The informed consent has been obtained from the patient.
- With confirmed diagnosis of stage II colon cancer.
- With moderate/good ECOG health rating (PS): 0-1 score.
- The patient receive no anti-cancer treatment before primary surgery.
- The patient receive radical operation for colon cancer with negative margin.
Exclusion Criteria:
- With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.
- With bad compliance or contraindication to enrollment.
- Pregnant woman or lactating woman.
- With contraindication to receive adjuvant chemotherapy.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: An experimental group
A 6 microRNA stratified tool is applied in this group.Investigators defined high risk patient and low risk patient according to the microRNA stratified tool.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
|
Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool.
MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215.
Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1).
Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
|
Annen: A control group
A classic stratified tool is applied in this group.
Investigators defined high risk and low risk patient according to classical pathological features.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
|
Investigators randomly assign patients to be assessed by by classical pathological features.
Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and <12 lymph nodes examined.
Investigators defined high risk patient if they had any pathological features, the others as low risk patient.
The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Disease free survival
Tidsramme: 3 years or 5 years
|
3 years or 5 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Overall survival
Tidsramme: 5 years or 10 years
|
5 years or 10 years
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Studieleder: Wu Song, MD, First Affiliated Hospital, Sun Yat-Sen University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2016
Primær fullføring (Forventet)
1. januar 2026
Studiet fullført (Forventet)
1. januar 2026
Datoer for studieregistrering
Først innsendt
30. april 2015
Først innsendt som oppfylte QC-kriteriene
8. juni 2015
Først lagt ut (Anslag)
9. juni 2015
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
9. juni 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. juni 2015
Sist bekreftet
1. juni 2015
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2015[28]
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kolon neoplasmer
-
Guangzhou First People's HospitalFullført
-
University of Roma La SapienzaFullførtColonic DiverticulaBrasil, Italia, Litauen, Polen, Romania, Storbritannia, Venezuela
-
Maastricht University Medical CenterUkjent
-
King's College Hospital NHS TrustFullført
-
Cook Group IncorporatedFullførtKolonpolypp | Angiodysplasi | Colonic DiverticulaCanada
-
Oxford University Hospitals NHS TrustFullførtEndetarmskreft | Ulcerøs kolitt | Tykktarmskreft | KolondivertikulumStorbritannia
-
Rabin Medical CenterFullførtDesmoid fibromatose | Desmoid | Desmoid fibromatose i huden | Desmoid Neoplasm of Chest Wall | Desmoid-svulst forårsaket av somatisk mutasjon | Aggressive fibromatoser | Fibromatose DesmoidIsrael
Kliniske studier på A 6 microRNA stratified tool
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthFullførtVirussykdommer | InfluensaForente stater
-
National Institute of Allergy and Infectious Diseases...FullførtVirussykdommer | InfluensaForente stater
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthFullførtVirussykdommer | InfluensaForente stater
-
Charles University, Czech RepublicAktiv, ikke rekrutterendeBetennelse | Brannsår | Infeksjon, bakteriellTsjekkia
-
ALK-Abelló A/SFullført
-
Coopervision, Inc.Fullført
-
National Institute of Allergy and Infectious Diseases...FullførtInfluensa A-virus, H7N9-subtypeForente stater
-
University of WindsorPublic Health Agency of Canada (PHAC)RekrutteringSeksuelle overgrepCanada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)AvsluttetMultippelt myelom og plasmacelleteoplasmaForente stater
-
Biomedical Advanced Research and Development AuthorityFullførtInfluensa A-virus, H5N1-subtypeForente stater